To study BrM therapeutic response to ICB, we generated a panel of syngeneic immunocompetent preclinical models preserving BBB integrity by intracardiac (i.c.)injection of the M4 melanoma mouse cell line27 into syngeneic C57BL/6 mice. This evidence concerns the gene SMARCA2 and melanoma.